Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19111


P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.


Inclusion Criteria: - Advanced solid tumors refractory to (or intolerant of) established therapy known to provide clinical benefit, or for which there is no standard therapy - Age >= 18 years of age - Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1500/uL, hemoglobin ≥ 9 g/dL, platelets > 100,000/uL - Adequate liver function as defined by: bilirubin < 1.5 x ULN, AST, ALT and ALP < 2.5 x ULN, or < 5 x ULN with documented liver and/or bone metastases - Serum creatinine < 1.5 x ULN - ECOG status 0-1 - Availability of biopsy tumor tissue (or fine needle aspirate) for testing of P-cadherin expression - Tumor tissue (or fine needle aspirate) showing over-expression of P-cadherin - Must be able to give written informed consent - Be able to comply with scheduled study visits, treatment plans, laboratory tests and other procedures Exclusion Criteria: - Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of study entry - Patients with carcinomatous meningitis or untreated brain metastases. - History of significant low platelet count, and/or bleeding disorders, requiring medical or surgical intervention - History of significant bleeding episodes within 6 months, unless the source of bleeding has been resected



Primary Contact:

Study Director
Pfizer CT.gov Call Center

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19111
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.